Literature DB >> 11250971

Mitral regurgitation after anthracycline treatment for childhood malignancy.

J Allen1, J D Thomson, I J Lewis, J L Gibbs.   

Abstract

OBJECTIVE: To investigate the new onset of mitral regurgitation in patients with otherwise normal echocardiograms after anthracycline treatment and to assess its relation to other selected indicators of myocardial damage.
DESIGN: Prospective echocardiographic and electrocardiographic study.
SETTING: Tertiary paediatric cardiac referral centre. PATIENTS: 305 patients, aged 2-33 years (median 14 years), treated with cumulative anthracycline doses of between 150-450 mg/m(2) (median 180 mg/m(2)) for childhood malignancy. MAIN OUTCOME MEASURES: Colour flow Doppler detection of mitral regurgitation and its relation to changes in echocardiographic indices of left ventricular function (systolic and diastolic dimensions, fractional shortening) and to changes in the 12 lead ECG; and the prevalence of mitral regurgitation in the anthracycline treated patients in comparison with previously studied normal volunteers of similar age.
RESULTS: 34 patients (11.6%) developed ultrasound detectable mitral regurgitation, which was not apparent clinically, during or after anthracycline treatment, compared with only 1.8% of a normal population of similar age (p < 0.0001). Nine of the 34 also developed non-specific T wave abnormalities. All 34 patients had normal systolic function at the time of initial detection of mitral regurgitation, but four later developed impaired left ventricular function (5, 11, 20, and 27 months after the first detection of mitral regurgitation).
CONCLUSIONS: Mitral regurgitation occurs much more often in patients treated with anthracyclines than in the normal population. Echocardiographic detection of new mitral regurgitation with or without ECG abnormalities may be an early predictor of anthracycline cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250971      PMCID: PMC1729680          DOI: 10.1136/heart.85.4.430

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  12 in total

1.  Left sided valvar regurgitation in normal children and adolescents.

Authors:  J D Thomson; J Allen; J L Gibbs
Journal:  Heart       Date:  2000-02       Impact factor: 5.994

2.  A paucity of chronic electrocardiographic changes with adriamycin therapy.

Authors:  S K Weaver; P K Fulkerson; R P Lewis; C V Leier
Journal:  J Electrocardiol       Date:  1978-07       Impact factor: 1.438

Review 3.  Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity.

Authors:  H G Keizer; H M Pinedo; G J Schuurhuis; H Joenje
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

4.  Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults.

Authors:  R L Larsen; R I Jakacki; V L Vetter; A T Meadows; J H Silber; G Barber
Journal:  Am J Cardiol       Date:  1992-07-01       Impact factor: 2.778

5.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

6.  Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity.

Authors:  M N Druck; K Y Gulenchyn; W K Evans; A Gotlieb; J R Srigley; B Z Bar-Shlomo; D H Feiglin; P McEwan; M D Silver; L Millband
Journal:  Cancer       Date:  1984-04-15       Impact factor: 6.860

7.  Clinical spectrum of anthracycline antibiotic cardiotoxicity.

Authors:  M R Bristow; M E Billingham; J W Mason; J R Daniels
Journal:  Cancer Treat Rep       Date:  1978-06

8.  Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer.

Authors:  C L Schwartz; W L Hobbie; S Truesdell; L C Constine; E B Clark
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

9.  Age-related valvular regurgitation: a study by pulsed Doppler echocardiography.

Authors:  T Akasaka; J Yoshikawa; K Yoshida; F Okumachi; K Koizumi; K Shiratori; S Takao; M Shakudo; H Kato
Journal:  Circulation       Date:  1987-08       Impact factor: 29.690

10.  The cardiotoxicity of anticancer agents.

Authors:  D D Von Hoff; M Rozencweig; M Piccart
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

View more
  7 in total

Review 1.  Valvular Heart Disease in Cancer Patients: Etiology, Diagnosis, and Management.

Authors:  Merrill H Stewart; Eiman Jahangir; Nichole M Polin
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

2.  Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation.

Authors:  Samo Zver; Vesna Zadnik; Peter Černelč; Mirta Koželj
Journal:  Int J Hematol       Date:  2008-06-12       Impact factor: 2.490

3.  Cardiac function in long-term survivors of childhood lymphoma.

Authors:  Mark K Friedberg; Ido Solt; Myriam Weyl-Ben-Arush; Yulia Braver; Avraham Lorber
Journal:  Cardiol Res Pract       Date:  2011-01-20       Impact factor: 1.866

Review 4.  Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography.

Authors:  Maurizio Galderisi; Francesco Marra; Roberta Esposito; Vincenzo Schiano Lomoriello; Moira Pardo; Oreste de Divitiis
Journal:  Cardiovasc Ultrasound       Date:  2007-01-25       Impact factor: 2.062

5.  The Value of Left Atrial Volume Changes in Predicting Cardiotoxicity in Patients Undergoing Anthracycline Chemotherapy.

Authors:  Dongliang Chen; Li Fan; Yifei Rui; Zining Yan
Journal:  J Healthc Eng       Date:  2022-03-24       Impact factor: 2.682

6.  Valvular Heart Disease following Anthracycline Therapy-Is It Time to Look beyond Ejection Fraction?

Authors:  David Zahler; Joshua H Arnold; Tali Bar-On; Ari Raphael; Shafik Khoury; Zach Rozenbaum; Shmuel Banai; Yaron Arbel; Yan Topilsky; Michal Laufer-Perl
Journal:  Life (Basel)       Date:  2022-08-20

7.  Mitral regurgitation after anthracycline-based chemotherapy in an adult patient with breast cancer: A case report.

Authors:  Xiaoyan Liu; Yanlin Zhu; Xue Lin; Ligang Fang; Xiaowei Yan
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.